SpeeDx Pty. Ltd. has received TGA approval for its PlexPCR™ HSV-1&2, VZV multiplex qPCR kit. The test offers a single-well solution to cover the detection and differentiation of three herpes viruses (HSV-1, HSV-2, VZV) in addition to an internal control. Validated for use on multiple lesion specimen types, the test is designed to streamline herpes testing workflows and support appropriate clinical and therapeutic management for infections that present similarly.
“We are delighted to receive TGA approval for this new high-performance benchmark for multiplex qPCR HSV and VZV testing,” said Colin Denver, CEO for SpeeDx. “This is the first test of many that we are excited to offer to the Australian market, following targeted and collaborative development with leading sexual health clinicians and researchers both here and around the world.”
The PlexPCR™ HSV-1&2, VZV kit is the first SpeeDx test to receive TGA approval.
Read the full press release here